- Home
- GERN vs CIM Comparison
GERN vs CIM Comparison
Compare GERN & CIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GERN
- CIM
- Stock Information
- Founded
- GERN 1990
- CIM 2007
- Country
- GERN United States
- CIM United States
- Employees
- GERN N/A
- CIM N/A
- Industry
- GERN Biotechnology: Pharmaceutical Preparations
- CIM Real Estate Investment Trusts
- Sector
- GERN Health Care
- CIM Real Estate
- Exchange
- GERN Nasdaq
- CIM Nasdaq
- Market Cap
- GERN 840.7M
- CIM 965.2M
- IPO Year
- GERN 1996
- CIM 2007
- Fundamental
- Price
- GERN $1.18
- CIM $12.63
- Analyst Decision
- GERN Buy
- CIM Hold
- Analyst Count
- GERN 9
- CIM 2
- Target Price
- GERN $5.13
- CIM $16.00
- AVG Volume (30 Days)
- GERN 11.5M
- CIM 527.4K
- Earning Date
- GERN 05-07-2025
- CIM 05-08-2025
- Dividend Yield
- GERN N/A
- CIM 11.72%
- EPS Growth
- GERN N/A
- CIM N/A
- EPS
- GERN N/A
- CIM 1.52
- Revenue
- GERN $116,293,000.00
- CIM $326,755,000.00
- Revenue This Year
- GERN $194.54
- CIM $11.59
- Revenue Next Year
- GERN $56.51
- CIM $2.13
- P/E Ratio
- GERN N/A
- CIM $8.31
- Revenue Growth
- GERN 22264.04
- CIM 11.90
- 52 Week Low
- GERN $1.17
- CIM $9.85
- 52 Week High
- GERN $5.34
- CIM $16.89
- Technical
- Relative Strength Index (RSI)
- GERN 32.46
- CIM 57.02
- Support Level
- GERN $1.34
- CIM $11.96
- Resistance Level
- GERN $1.44
- CIM $13.28
- Average True Range (ATR)
- GERN 0.10
- CIM 0.34
- MACD
- GERN 0.00
- CIM 0.16
- Stochastic Oscillator
- GERN 3.23
- CIM 67.73
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
About CIM Chimera Investment Corporation
Chimera Investment Corporation is a real estate investment trust engaged in investing in a portfolio of mortgage assets on a leveraged basis. These investments include a variety of government-sponsored agency residential mortgage-backed securities, or RMBS, non-agency RMBS, agency commercial mortgage-backed securities, residential mortgage loans, and other real estate-related securities. Agency mortgage-backed securities represent the share of this portfolio, while subprime residential mortgage loans and non-agency RMBS also make up substantial shares.